Phase 3
N=38
A Trial of Magnesium Dependent Tinnitus
Tinnitus
Bottom Line
View on ClinicalTrials.gov: NCT01273883 ↗Enrolled (actual)
38
Serious AEs
0.0%
Results posted
Jan 2015
Primary outcome: Primary: Tinnitus Distress Rating — 5.71; 5.82; 5.36; 5.46 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Magnesium (Dietary_supplement); Placebo (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Oct 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Tinnitus Distress Rating |
5.71; 5.82; 5.36; 5.46 | — |
| SECONDARY Comparison of Average Tinnitus Handicap Inventory (THI) Across All Subjects |
25.7; 25.7; 24.1; 23.2 | — |
| SECONDARY Comparison of Average Tinnitus Handicap Inventory (THI) Across All Men |
29.1; 27.2; 27.8; 25.3 | — |
| SECONDARY Comparison of Average Tinnitus Handicap Inventory (THI) Across All Women |
18.7; 22.6; 16.4; 18.4 | — |
Summary
The purpose of this study was to examine any potential benefit in lessening the severity of tinnitus (ringing or booming sensation in one or both ears) in subjects supplemented with magnesium (532 mg daily).
Eligibility Criteria
Inclusion criteria
- Normal Kidney function (last checked within 6 months). Serum creatinine levels 1.5 mg/dL or below for females, 2.0 mg/dL for males.
- An audiogram within the past 6 months
- Mayo Clinic patients who live in Phoenix area
Exclusion criteria
- Any participant with decreased kidney function within past 6 months, over 1.5 mg/dL for females and over 2.0 mg/dL for males.
- Current treatment with Lithium
- Tinnitus rating with 0, 1, or 2 on the 0-10 Tinnitus scale
Data sourced from ClinicalTrials.gov (NCT01273883). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.